Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015, Article ID 737302, 4 pages
http://dx.doi.org/10.1155/2015/737302
Case Report

Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant)

1Department of Internal Medicine, Faenza Hospital, Viale Stradone 9, 48018 Faenza, Italy
2Department of Clinical Pathology, Centro Servizi Pievesestina, AUSL Romagna, Piazzale della Liberazione 60, Pievesestina, 47522 Cesena, Italy
3Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy

Received 16 August 2014; Revised 7 January 2015; Accepted 13 January 2015

Academic Editor: Stephen Langabeer

Copyright © 2015 P. Savini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Lennert and M. R. Parwaresch, “Mast cells and mast cell neoplasia: a review,” Histopathology, vol. 3, no. 5, pp. 349–365, 1979. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Valent, K. Sotlar, W. R. Sperr, A. Reiter, M. Arock, and H.-P. Horny, “Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features,” Leukemia Research, vol. 39, no. 1, pp. 1–5, 2015. View at Publisher · View at Google Scholar
  3. H. P. Horny, D. D. Metcalfe, J. M. Bennett et al., “Mastocytosis,” in WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, S. H. Swerdlow, E. Campo, N. L. Harris, and etal, Eds., pp. 54–63, International Agency for Researchand Cancer (IARC), Lyon, France, 2008. View at Google Scholar
  4. P. Valent, M. Arock, C. Akin et al., “The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non–mast cell lineage disease (SM-AHNMD),” Blood, vol. 116, no. 5, pp. 850–851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Valent, C. Akin, W. R. Sperr, H. P. Horny, and D. D. Metcalfe, “Mast cell proliferative disorders: current view on variants recognized by the World Health Organization,” Hematology/Oncology Clinics of North America, vol. 17, no. 5, pp. 1227–1241, 2003. View at Publisher · View at Google Scholar
  6. S. Georgin-Lavialle, L. Lhermitte, P. Dubreuil, M.-O. Chandesris, O. Hermine, and G. Damaj, “Mast cell leukemia,” Blood, vol. 121, no. 8, pp. 1285–1295, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. K.-H. Lim, A. Tefferi, T. L. Lasho et al., “Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors,” Blood, vol. 113, no. 23, pp. 5727–5736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. L. B. Schwartz, “Diagnostic value of tryptase inanaphylaxis and mastocytosis,” Immunology and Allergy Clinics of North America, vol. 26, no. 3, pp. 451–463, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Pardanani, “Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management,” American Journal of Hematology, vol. 86, no. 4, pp. 362–371, 2011. View at Publisher · View at Google Scholar · View at Scopus